513

MK-2206 dihydrochloride

513 Publications Verification

Cat. No.: HY-10358

CAS No.: 1032350-13-2

Purity: 99.94%

Synonyms: MK-2206 (2HCl)

Target:

Bcl-2 Family Apoptosis mTOR Akt GSK-3

Research Areas:

Cardiovascular Disease Inflammation/Immunology Cancer

MK-2206 dihydrochloride (MK-2206 2HCl) is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 dihydrochloride inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 dihydrochloride induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 dihydrochloride causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 dihydrochloride can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

513

MK-2206

513 Publications Verification

Cat. No.: HY-108232

CAS No.: 1032349-77-1

Purity: 99.72%

Target:

Bcl-2 Family Apoptosis mTOR Akt GSK-3

Research Areas:

Metabolic Disease Inflammation/Immunology Cancer

MK-2206 is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

60

Fatostatin

60 Cited Publications

Cat. No.: HY-14452

CAS No.: 125256-00-0

Purity: 99.85%

Synonyms: 125B11

Target:

Fatty Acid Synthase (FASN)

Research Areas:

Cancer

Fatostatin (125B11), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin decreases the transcription of lipogenic genes in cells. Fatostatin possesses antitumor properties, and lowers hyperglycemia in ob/ob mice .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

60

Fatostatin hydrobromide

60 Cited Publications

Cat. No.: HY-14452A

CAS No.: 298197-04-3

Purity: 99.52%

Synonyms: 125B11 hydrobromide

Target:

Fatty Acid Synthase (FASN)

Research Areas:

Cancer

Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

(+)-Afzelechin

4 Cited Publications

Cat. No.: HY-N2821

CAS No.: 2545-00-8

Category:

Saxifragaceae Extract Flavonoids Flavanols Metabolic Disease Phenols Polyphenols Plants Disease Research Fields

Target:

Glycosidase

(+)-Afzelechin, isolated from rhizomes of Bergenia ligulata, is an alpha-glucosidase activity inhibitor with an ID₅₀ (50% inhibition dose) value of 0.13 mM. (+)-Afzelechin can delay the absorption of carbohydrates in food to suppress postprandial hyperglycemia and hyperinsulinemia .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

Vatinoxan hydrochloride

3 Cited Publications

Cat. No.: HY-19057A

CAS No.: 130466-38-5

Synonyms: MK-467 hydrochloride; L-659066 hydrochloride

Target:

Adrenergic Receptor

Vatinoxan hydrochloride (MK-467 hydrochloride) is a peripherally selective α₂-Adrenoceptor antagonist. Vatinoxan hydrochloride blocks peripheral α2-adrenoceptor-mediated vasoconstriction, bradycardia, hyperglycemia, diuresis, lens opacity, and decreased intraocular pressure, delays pupil dilation, and maintains corneal thickness. Vatinoxan hydrochloride, when combined with Medetomidine (HY-17034)/benzodiazepines, reduces respiratory rate and increases pulse rate, cutaneous microcirculation, tissue oxygenation, peripheral heat loss, and cardiac index, while altering gastrointestinal perfusion and mean arterial pressure, without causing death, hypotension, or hypoglycemia, and blocks vasoconstriction of chelonian resistance arteries .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

Coluracetam

3 Cited Publications

Cat. No.: HY-17553

CAS No.: 135463-81-9

Synonyms: MKC-231

Target:

iGluR

Research Areas:

Neurological Disease

Coluracetam (MKC-231) is an orally taken choline uptake enhancer. Coluracetam can improve the reduced acetylcholine levels in the hippocampus of rats and mice, enhancing learning difficulties, memory deficits, and cognitive impairments. Coluracetam induces a lower degree of hepatic venous hyperglycemia .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

Vatinoxan

3 Cited Publications

Cat. No.: HY-19057

CAS No.: 114914-42-0

Synonyms: MK-467; L-659066

Target:

Adrenergic Receptor

Research Areas:

Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology

Vatinoxan (MK-467) is a peripherally selective α₂-Adrenoceptor antagonist. Vatinoxan blocks peripheral α2-adrenoceptor-mediated vasoconstriction, bradycardia, hyperglycemia, diuresis, lens opacity, and decreased intraocular pressure, delays pupil dilation, and maintains corneal thickness. Vatinoxan, when combined with Medetomidine (HY-17034)/benzodiazepines, reduces respiratory rate and increases pulse rate, cutaneous microcirculation, tissue oxygenation, peripheral heat loss, and cardiac index, while altering gastrointestinal perfusion and mean arterial pressure, without causing death, hypotension, or hypoglycemia, and blocks vasoconstriction of chelonian resistance arteries .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

Tolazamide

2 Cited Publications

Cat. No.: HY-B0920

CAS No.: 1156-19-0

Synonyms: U-17835

Target:

Potassium Channel

Research Areas:

Metabolic Disease Endocrinology

Tolazamide (U-17835) is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC₅₀ = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

DI-1859

2 Cited Publications

Cat. No.: HY-145733

CAS No.: 2247061-09-0

Purity: 99.62%

Target:

E1/E2/E3 Enzyme Keap1-Nrf2 Reactive Oxygen Species (ROS) Insulin Receptor Akt

Research Areas:

Metabolic Disease Cancer

DI-1859 is a DCN1 and cullin 3 inhibitor with a K_i of <1 nM against human DCN1. DI-1859 forms a covalent bond with Cys115 of DCN1, cleaves its dimethylamino group, disrupts the DCN1-UBC12 interaction, and selectively inhibits the neddylation modification of cullin 3 relative to other cullins. DI-1859 inactivates CRL3, promotes the accumulation of NRF2 and SLC7A11, upregulates the expression of HO-1 and NQO1, reduces reactive oxygen species (ROS) levels, enhances insulin signaling, promotes insulin secretion, activates RhoA, regulates the phosphorylation of AKT, without completely blocking the neddylation modification of cullin 3 or restoring the expression of IRS-1. DI-1859 can be used in the research of Acetaminophen (HY-66005)-induced hepatotoxicity, hyperglycemia, metabolic dysfunction-associated steatotic liver disease, insulin resistance, breast cancer and lung cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

N6-(2-Hydroxyethyl)adenosine

1 Cited Publications

Cat. No.: HY-W006957

CAS No.: 4338-48-1

Target:

Nucleoside Antimetabolite/Analog Insecticide NF-κB TGF-beta/Smad Reactive Oxygen Species (ROS) Apoptosis Autophagy Mitochondrial Metabolism SOD

Research Areas:

Cardiovascular Disease Inflammation/Immunology Cancer

N6-(2-Hydroxyethyl)adenosine is a purine nucleoside analog. N6-(2-Hydroxyethyl)adenosine inhibits NF-κB/Smad signaling pathway, exhibits anti-hyperglycemia, antioxidant, antitumor and anti-inflammatory and insecticidal activities. N6-(2-Hydroxyethyl)adenosine is orally active .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

FeTMPyP

1 Cited Publications

Cat. No.: HY-120380

CAS No.: 133314-07-5

Purity: 99.8%

Target:

MOFs PARP

Research Areas:

Neurological Disease

FeTMPyP is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. FeTMPyP inhibits cell death, nitrotyrosine formation, and depolarization of mitochondrial transmembrane potential. FeTMPyP reduces homocysteine-induced nitrosative stress and partially restores TFEB protein and mRNA levels. FeTMPyP improves functional and behavioral deficits caused by chronic constriction injury in rats. FeTMPyP alleviates acute cerebral infarction in a rat model of middle cerebral artery occlusion with mild hyperglycemia. FeTMPyP can be used in studies related to neuropathic pain, renal aging, ischemic penumbra, and hyperglycemic stroke .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Mergetpa

1 Cited Publications

Cat. No.: HY-W704574

CAS No.: 77102-28-4

Target:

Carboxypeptidase Bradykinin Receptor Interleukin Related

Research Areas:

Cardiovascular Disease Metabolic Disease

Mergetpa is a reversible Arg-carboxypeptidase inhibitor with high affinity. Mergetpa reduces B1R. Mergetpa blocks the overexpression of IL-1β protein and mRNA in glucose-fed rats. Mergetpa significantly increases the expression of IL-1β protein in the renal cortex. Mergetpa is used to block the conversion of kinins and B2 receptor antagonists into metabolites lacking the C-terminal arginine. Mergetpa inhibits the time-dependent enhancement of the response of isolated rabbit aorta to bradykinin. Mergetpa preserves the chemotactic activity of full-length SDF-1α on cells. Mergetpa reverses hyperglycemia, excessive weight gain, elevated levels of oxidative stress markers and overexpression of inflammatory markers in glucose-fed rats .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

D-Lysine

1 Cited Publications

Cat. No.: HY-Y1091

CAS No.: 923-27-3

Category:

Other Diseases Amino acids Endogenous metabolite Disease Research Fields

Target:

Drug Isomer

D-Lysine is the D-enantiomer of L-Lysine (HY-N0469). D-Lysine is metabolically inert and not utilized for protein synthesis by mammalian ribosomes. D-Lysine blocks renal uptake of ¹¹¹In/ ⁹⁰Y-Octreotide (HY-P0036)-based probes without inhibiting uptake by tumor/receptor tissues, and thus acts as a renoprotective agent in diagnostic imaging and peptide receptor radionuclide therapy (PRRT). D-Lysine specifically inhibits the early steps of non-enzymatic glycation by competing with glucose via its free amino group, theoretically, it can serve as a glycation competitor that "does not interfere with protein synthesis" under chronic hyperglycemia in diabetes. D-Lysine can be used in research related to cancer and diabetes .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

D-Lysine monohydrochloride

1 Cited Publications

Cat. No.: HY-Y1804

CAS No.: 7274-88-6

Category:

Other Diseases Amino acids Endogenous metabolite Disease Research Fields

Target:

Drug Isomer

D-Lysine monohydrochloride is the D-enantiomer of L-Lysine (HY-N0469). D-Lysine monohydrochloride is metabolically inert and not utilized for protein synthesis by mammalian ribosomes. D-Lysine monohydrochloride blocks renal uptake of ¹¹¹In/ ⁹⁰Y-Octreotide (HY-P0036)-based probes without inhibiting uptake by tumor/receptor tissues, and thus acts as a renoprotective agent in diagnostic imaging and peptide receptor radionuclide therapy (PRRT). D-Lysine monohydrochloride specifically inhibits the early steps of non-enzymatic glycation by competing with glucose via its free amino group, theoretically, it can serve as a glycation competitor that "does not interfere with protein synthesis" under chronic hyperglycemia in diabetes. D-Lysine monohydrochloride can be used in research related to cancer and diabetes .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Calcium mesoxalate trihydrate

1 Cited Publications

Cat. No.: HY-W540188A

Synonyms: Ketomalonic acid calcium trihydrate; Mesoxalic acid calcium trihydrate; Oxomalonic acid calcium trihydrate

Target:

Insulin Receptor

Research Areas:

Metabolic Disease

Calcium mesoxalate trihydrate (Ketomalonic acid calcium trihydrate) is an orally active antidiabetic agent. Calcium mesoxalate trihydrate increases pancreatic insulin content. Calcium mesoxalate trihydrate reduces dietary hyperglycemia. Calcium mesoxalate trihydrate inhibits Epinephrine-induced hyperglycemia in rabbits and exacerbates Alloxan (HY-116823)-induced hypoglycemic convulsions. Calcium mesoxalate trihydrate exerts no antidiabetic effect in pancreatectomized dogs and fails to reduce the susceptibility of rabbits to Alloxan-induced diabetes. Calcium mesoxalate trihydrate can be used in diabetes-related research .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Seladelpar (lysine dihydrate)

1 Cited Publications

Cat. No.: HY-19522C

CAS No.: 928821-40-3

Synonyms: MBX-8025 (lysine dihydrate); RWJ-800025 (lysine dihydrate)

Target:

PPAR Interleukin Related

Research Areas:

Cardiovascular Disease Metabolic Disease Inflammation/Immunology

Seladelpar Lysine dihydrate (MBX-8025 lysine dihydrate) is an orally active, selective PPAR-δ agonist with an EC₅₀ of 2 nM against hPPAR-δ. Seladelpar Lysine dihydrate reduces serum IL-31 and bile acid levels. It alleviates pruritus symptoms. Seladelpar Lysine dihydrate enhances insulin sensitivity, normalizes levels of hyperglycemia, hyperinsulinemia, glucose disposal capacity, serum lipids and hepatic free cholesterol. It reduces steatosis, hepatic inflammation and improves liver fibrosis. Seladelpar Lysine dihydrate reverses the pathological changes of non-alcoholic steatohepatitis (NASH). It is applicable to research related to primary biliary cholangitis and non-alcoholic steatohepatitis (NASH) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Sequoyitol

1 Cited Publications

Cat. No.: HY-N2421

CAS No.: 523-92-2

Synonyms: 5-O-Methyl-myo-inositol

Category:

Natural Products 500 - Internal Server Error | MedChemExpress

country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Cart

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Oops!

Sorry, Something went wrong on our server.
Our team has been notified and is working to fix the issue.

Hyperglycemia

Oops!